|
|
||||||||
1 From the Molecular and Developmental Biology Laboratory, Department of Ophthalmology, Johns Hopkins University School of Medicine; and 2 Johns Hopkins Center for Hereditary Eye Diseases, Wilmer Ophthalmological Institute, Baltimore, Maryland.
| Abstract |
|---|
|
|
|---|
METHODS. The human CRX gene was sequenced in 74 consecutive patients carrying the diagnosis of Leber congenital amaurosis.
RESULTS. Two mutations were identified in CRX that cause frameshifts and predict severe truncations of the encoded protein. One of these, a 1-bp insertion, spares only nine N-terminal amino acids, removing the homeodomain, WSP motif, and conserved OTX domain at the C terminus. Of the CRX mutations described in the literature, this is the first that convincingly represents a null allele of the gene. Although the patient heterozygous for this null allele is affected with Leber congenital amaurosis, it was surprising that her father, who had normal vision, was heterozygous for the same mutation.
CONCLUSIONS. These results strongly suggest that haploinsufficiency of CRX is not sufficient to cause a retinal disorder. Loss of function alleles of CRX appear to cause Leber congenital amaurosis through a recessive or multigenic mechanism.
| Introduction |
|---|
|
|
|---|
It is estimated that LCA accounts for 10% of childhood blindness. Although LCA is generally thought to be inherited in an autosomal recessive fashion, some autosomal dominant pedigrees have been reported.4 5 The disease is genetically heterogeneous, and to date six independent loci for LCA have been linked to chromosomes 1p31,6 7 6q11-16,8 14q24,9 17p13.1,10 17p13.3,11 and 19q13.12 Mutations have been reported in the RPE65 gene on 1p31,6 7 11 the AIPL1 gene on 17p13.1, and the GUCY2D gene on 17p13.311 in families in which the autosomal recessive mode of transmission has been observed. In contrast, mutations in the CRX gene have followed both the dominant5 10 and recessive13 modes of inheritance.
In this report we describe novel mutations in the CRX gene of patients with LCA, and we discuss the possible mechanisms of action underlying these changes.
| Materials and Methods |
|---|
|
|
|---|
Mutation Analysis
Genomic DNA was prepared from peripheral blood by
phenol-chloroform extraction or using the QIamp blood kit (Qiagen,
Santa Clarita, CA) according to manufacturers instructions.
Polymerase chain reaction (PCR) amplification was obtained from genomic
DNA using previously published sets of primers.14
After
PCR amplification, fragments were analyzed on a 8% polyacrylamide gel
and visualized by ethidium bromide staining. To sequence the amplimers
individually, these were separated on a 1.6% low-melting-point
agarose, and the bands were excised and treated with
ß-agarase and subsequently phenol-chloroform purified. The
purified products were used for direct manual sequencing using a cycle
sequencing kit with 33P-labeled dideoxy
nucleotides (Thermo Sequenase; Amersham, Life Sciences, Arlington, IL),
according to the manufacturers instructions. To further confirm the
mutations, the gel purified amplimers were cloned into the pCR 2.1-TOPO
vector, using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA)
according to the manufacturers recommendations. For each of the two
probands, 10 different amplimer subcloned fragments were sequenced at
the Johns Hopkins University core facility, using the ABI 100, version
3.2 automated sequencer (ABI prism; Applied Biosystems, Foster City,
CA).
| Results |
|---|
|
|
|---|
1bp; Fig. 2B
). No missense, nonsense or splice-site
mutations were identified in this group. Both mutations cause
frameshifts that predict significant changes in protein structure (Fig. 3) .
|
|
|
A very different situation is provided by the L237
1bp frameshift
mutation. In this case, the predicted protein does not have 21% of the
C-terminal tail, including the conserved OTX tail motif and C-terminus.
This frameshift eliminates the original stop codon. The missing amino
acids are replaced by a new C-terminus that determines a 369-amino acid
protein derived from an alternate reading frame and the normal 3'
untranslated region. These mutations were not found in the
CRX gene of 208 control individuals. These two patients also
were screened for mutations in GUCY2D and RPE65,
but the results were negative.
Sequence analysis demonstrated that the c.709delC mutation was absent in both parents, who had normal visual function, indicating its de novo origin in association with the disease. Ophthalmoscopic examination of the 18-month-old proband was unremarkable; however, the ERG was abolished.
In contrast, sequence analysis showed that the father of the proband with the c.25insG allele also carried this insertion mutation. It should be underscored that in both cases parentage was tested and confirmed. A surprising finding was that the father who carried the c.25insG mutation did not show any significant clinical abnormalities. Ophthalmologic examination of the fundus, fluorescein angiography, and color testing all produced normal results. ERG results revealed normal scotopic responses and only a very mild reduction in the photopic flash responses. This ERG profile is also observed in a significant percentage of normal individuals in the same age group. Another surprising feature is the finding that, since birth, the proband had had severe bilateral sensorineural hearing loss for all frequency ranges.
| Discussion |
|---|
|
|
|---|
The observation that a heterozygous null mutation such as c.25insG has no obvious phenotype eliminates haploinsufficiency as the disease-causing mechanism. However, we cannot exclude the presence of mutations outside the coding regions of the other, maternal CRX allele. Such mutations may affect promoter function and splicing or reduce the stability of the mRNA. Any of these possibilities would be consistent with an autosomal recessive model and could account for the dramatic differences in phenotype observed between the father and the proband. Another possible explanation is digenic inheritance (e.g., with the NRL gene)specifically, double heterozygosity of two interacting mutations. In this context, we also screened for mutations in GUCY2D and RPE65 genes known to cause LCA and found no sequence changes. We could also conceive that a variant of the CRX promoter produces higher than normal levels of mRNA of the wild-type allele, suppressing disease in the father by boosting CRX protein above a critical threshold. Other explanations for this phenotypic variation include the possibility of somatic mosaicism in the father, genetic imprinting of the wild-type CRX allele, or environmental factors that could influence the normal course of retinal development and enhance the effect of the mutant allele.
In contrast, the c.709delC allele will produce a protein that has
retained its DNA-binding homeodomain but has lost its OTX-conserved
motif and C-terminal domain. This mutation closely fits the category
described earlier by Freund et al.12
for which
haploinsufficiency and dominantnegative effects were discussed as
possible disease-causing mechanisms. Functional studies of the PAX6
protein have recently demonstrated that truncation mutations in the
C-terminal transactivation region of PAX6 result in
dominantnegative mutants.17
By analogy with the
PAX6 studies, retention of the CRX homeodomain in
the defective L237
1bp protein may allow it to compete for DNA
binding sites with the functional wild-type transcription factor.
Biochemical studies should give insight to the functional consequences
of this mutation. These new findings bring a new perspective to the
role of heterozygous CRX mutations in ocular disease and
reinforce the need for caution when genetic counseling is requested by
patients and their families.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication March 16, 1999; revised August 27, 1999, and January 24, 2000; accepted February 15, 2000.
Commercial relationships policy: N.
Corresponding author: Eduardo Silva, Maumenee Building Suite 517, The Wilmer Ophthalmological Institute, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287-9237. esilva{at}jhmi.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. A. Smyth, D. Di Lorenzo, and B. N. Kennedy A Novel, Evolutionarily Conserved Enhancer of Cone Photoreceptor-specific Expression J. Biol. Chem., April 18, 2008; 283(16): 10881 - 10891. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schuster, A. R. Janecke, R. Wilke, E. Schmid, D. A. Thompson, G. Utermann, B. Wissinger, E. Zrenner, and A. Gal The Phenotype of Early-Onset Retinal Degeneration in Persons with RDH12 Mutations Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1824 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Ferreira Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R259 - R267. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Lu, M. Guruju, J. Oswald, and P. A. Ferreira Limited proteolysis differentially modulates the stability and subcellular localization of domains of RPGRIP1 that are distinctly affected by mutations in Leber's congenital amaurosis Hum. Mol. Genet., May 15, 2005; 14(10): 1327 - 1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dharmaraj, B. P. Leroy, M. M. Sohocki, R. K. Koenekoop, I. Perrault, K. Anwar, S. Khaliq, R. S. Devi, D. G. Birch, E. De Pool, et al. The Phenotype of Leber Congenital Amaurosis in Patients With AIPL1 Mutations Arch Ophthalmol, July 1, 2004; 122(7): 1029 - 1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. M. Cremers, J. A. J. M. van den Hurk, and A. I. den Hollander Molecular genetics of Leber congenital amaurosis Hum. Mol. Genet., May 15, 2002; 11(10): 1169 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chen, Q.-L. Wang, S. Xu, I. Liu, L. Y. Li, Y. Wang, and D. J. Zack Functional analysis of cone-rod homeobox (CRX) mutations associated with retinal dystrophy Hum. Mol. Genet., April 15, 2002; 11(8): 873 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Bibb, J. K.L. Holt, E. E. Tarttelin, M. D. Hodges, K. Gregory-Evans, A. Rutherford, R. J. Lucas, J. C. Sowden, and C. Y. Gregory-Evans Temporal and spatial expression patterns of the CRX transcription factor and its downstream targets. Critical differences during human and mouse eye development. Hum. Mol. Genet., July 1, 2001; 10(15): 1571 - 1579. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Tzekov, Y. Liu, M. M. Sohocki, D. J. Zack, S. P. Daiger, J. R. Heckenlively, and D. G. Birch Autosomal Dominant Retinal Degeneration and Bone Loss in Patients with a 12-bp Deletion in the CRX Gene Invest. Ophthalmol. Vis. Sci., May 1, 2001; 42(6): 1319 - 1327. [Abstract] [Full Text] |
||||
![]() |
K.-Y. Chau, S. Chen, D. J. Zack, and S. J. Ono Functional Domains of the Cone-Rod Homeobox (CRX) Transcription Factor J. Biol. Chem., November 17, 2000; 275(47): 37264 - 37270. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |